PIIND PI Industries Q1 FY26 results (Apr–Jun 2025) and concall
PI Industries reported a mixed Q1 FY26 with an 8% YoY revenue decline to ₹19,005 million, primarily due to softness in AgChem exports and regulatory challenges in domestic biologicals. Despite this, the pharma business showed robust 186% YoY growth, and gross margins expanded to 57.4%. The company maintains its FY26 single-digit revenue growth guidance, expecting acceleration in H2, driven by new product commercializations and resolution of biological regulatory issues.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 |
|---|---|---|---|---|
| Revenue | 2,221 | 1,901 | 1,787 | 1,900 |
| EBITDA | 628 | 512 | 456 | 519 |
| Net profit | 508 | 373 | 330 | 400 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
